Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

David Carcedo Rodriguez

13PUBLICATIONS

39CO-AUTHORS

Gene and molecular therapyPredictive and prognostic markersLiquid biopsiesMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|Feb 27, 2026

A Response to: Letter to the Editor Regarding "Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain".

Virginia Lozano, Julia Llinares, Patrick Halavacek

|Apr 07, 2025

Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain.

Cristina Encinas, Virginia Lozano, Patrick Hlavacek

|Dec 19, 2024

Cost-effectiveness of a machine learning risk prediction model (LungFlag) in the selection of high-risk individuals for non-small cell lung cancer screening in Spain.

Juan Carlos Trujillo, Joan B Soriano, Mercè Marzo

|Oct 10, 2024

Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis.

Dolores Isla, Rosa Álvarez, María Arnal

|Jan 12, 2024

Actionable mutational profiling in solid tumors using hybrid-capture-based next-generation sequencing in a real-world setting in Spain.

Sandra Zazo, Sandra Pérez-Buira, Nerea Carvajal

|Mar 08, 2023

Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1.

Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Javier De Castro

Pageof 3

Frequent Collaborators

3 joint publications

Reyes Bernabé-Caro

2 joint publications

Ernest Nadal

2 joint publications

Enrique de Alava

2 joint publications

María Jesús Pareja

2 joint publications

Amelia Insa

2 joint publications

Roberto Collado-Borrell

2 joint publications

Vicente Escudero-Vilaplana

2 joint publications

Elena Fernandez

2 joint publications

Alba Manzaneque

2 joint publications

Edurne Arriola

Frequent Collaborators

3 joint publications

Reyes Bernabé-Caro

2 joint publications

Ernest Nadal

2 joint publications

Enrique de Alava

2 joint publications

María Jesús Pareja

Top Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on : Feb 17, 2022

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

Published on : Oct 26, 2017

See more related videos

Top Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on : Feb 17, 2022

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

Published on : Oct 26, 2017

See more related videos